{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T14:59:42Z","timestamp":1785423582567,"version":"3.56.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>The aim of this review is to describe the substantial advances that have been made in the past 2 years on new treatment options in eosinophilic granulomatosis with polyangiitis (EGPA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>The therapeutic scenario in EGPA has been recently broadened by the publication of the results from the multicenter, double-blind randomized MANDARA trial, which proved the noninferiority of benralizumab to another anti-interleukin-5 (IL-5) drug, mepolizumab, for the induction of remission in patients with EGPA. A few real-world studies have confirmed these results. Furthermore, the first randomized controlled trial exploring the efficacy of rituximab (anti-CD20) in induction of remission of EGPA was recently published. Targeting other molecular pathways did not always show adequate control of systemic manifestations of EGPA, with only limited evidence of effectiveness from small case series. Interestingly, cases of EGPA onset in severe asthma patients treated with monoclonal antibodies were described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Biological drug therapy targeting IL-5 consolidated its role in the management of EGPA, becoming the cornerstone of the treatment of this rare disease. Future guidelines should consider these recent findings to improve the management of EPGA. Notably, while selective IL-5 targeting is highly effective for remission maintenance, its role in inducing remission in EGPA remains to be fully established. Rituximab was non-superior to standard therapy in induction of remission in patients with EGPA, demonstrating a similar rate of response. The role of other targeted therapies, albeit promising in some cases, remains a matter of debate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000001148","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:00:07Z","timestamp":1771588807000},"page":"182-190","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Eosinophilic granulomatosis with polyangiitis: recent therapeutic advances"],"prefix":"10.1097","volume":"38","author":[{"given":"Emanuele","family":"Chiara","sequence":"first","affiliation":[{"name":"Department of Medical, Surgery and Health Sciences, University of Trieste, Italy and Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelangelo","family":"Tesi","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Meyer Children's Hospital, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Emmi","sequence":"additional","affiliation":[{"name":"Department of Medical, Surgery and Health Sciences, University of Trieste, Italy and Clinical Medicine and Rheumatology Unit, Cattinara University Hospital, Trieste"},{"name":"Department of Medicine, Centre for Inflammatory Diseases, Monash Medical Centre, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Vaglio","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Meyer Children's Hospital, Florence, Italy"},{"name":"Department of Biomedical Experimental and Clinical Sciences \u201cMario Serio\u201d, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"R1-20260401","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"R2-20260401","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis: a European Multicenter Observational Study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R3-20260401","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N Engl J Med"},{"key":"R4-20260401","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.7326\/ANNALS-24-03947","article-title":"Rituximab versus conventional therapy for remission induction in eosinophilic granulomatosis with polyangiitis: a randomized controlled trial","volume":"178","author":"Terrier","year":"2025","journal-title":"Ann Intern Med"},{"key":"R5-20260401","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/mr\/roaf014","article-title":"Systematic literature review and meta-analysis of the epidemiology and clinical burden of eosinophilic granulomatosis with polyangiitis","volume":"35","author":"Dolin","year":"2025","journal-title":"Mod Rheumatol"},{"key":"R6-20260401","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41584-023-00958-w","article-title":"Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis","volume":"19","author":"Emmi","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"R7-20260401","doi-asserted-by":"crossref","first-page":"885198","DOI":"10.3389\/fimmu.2022.885198","article-title":"Clinical significance of MPO-ANCA in eosinophilic granulomatosis with polyangiitis: experience from a longitudinal Chinese cohort","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"R8-20260401","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1093\/rheumatology\/keaa805","article-title":"Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"60","author":"Papo","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R9-20260401","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-019-12515-9","article-title":"Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status","volume":"10","author":"Lyons","year":"2019","journal-title":"Nat Commun"},{"key":"R10-20260401","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.alit.2023.09.001","article-title":"Reduction in ANCA levels associated with mepolizumab add-on treatment in eosinophilic granulomatosis with polyangiitis: Case series and literature review","volume":"73","author":"Kamide","year":"2024","journal-title":"Allergol Int"},{"key":"R11-20260401","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1136\/ard-2023-224756","article-title":"Dupilumab for relapsing or refractory sinonasal and\/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study","volume":"82","author":"Molina","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"(Suppl 9)","key":"R12-20260401","article-title":"Tezepelumab for relapsing or refractory eosinophilic granulomatosis with polyangiitis: a european retrospective study [abstract]","volume":"76","author":"Poux","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"R13-20260401","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.chest.2025.05.015","article-title":"Tezepelumab in patients with eosinophilic granulomatosis with polyangiitis after suboptimal response to anti-IL5\/5R Therapy","volume":"168","author":"Nanzer","year":"2025","journal-title":"Chest"},{"key":"R14-20260401","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.1093\/rheumatology\/keaf397","article-title":"Tofacitinib in combination with glucocorticoids in the treatment of eosinophilic granulomatosis with polyangiitis: a pilot study of 11 cases","volume":"64","author":"Liu","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"R15-20260401","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R16-20260401","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/mr\/roae100","article-title":"Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: long-term observation of the MARS study","volume":"35","author":"Ishii","year":"2025","journal-title":"Mod Rheumatol"},{"key":"R17-20260401","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1093\/rheumatology\/keaf201","article-title":"Step-down treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis: a real-life single-centre study","volume":"64","author":"Moroni","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"R18-20260401","first-page":"4937","article-title":"Impact of mepolizumab on the AAV-PRO questionnaire in eosinophilic granulomatosis with polyangiitis: data from a European multicentre study","volume":"64","author":"Delvino","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"R19-20260401","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard-2023-224624","article-title":"Benralizumab for eosinophilic granulomatosis with polyangiitis","volume":"82","author":"Cottu","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R20-20260401","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1136\/ard-2022-222776","article-title":"Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study","volume":"81","author":"Bettiol","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R21-20260401","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.ard.2025.06.2131","article-title":"Two-year efficacy and safety of anti-interleukin-5\/receptor therapy for eosinophilic granulomatosis with polyangiitis","volume":"84","author":"Merkel","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"R22-20260401","doi-asserted-by":"crossref","first-page":"103398","DOI":"10.1016\/j.jaut.2025.103398","article-title":"Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): A European real-life retrospective comparative study","volume":"153","author":"Mattioli","year":"2025","journal-title":"J Autoimmun"},{"key":"R23-20260401","doi-asserted-by":"crossref","first-page":"e14333","DOI":"10.1111\/eci.14333","article-title":"Efficacy and safety of benralizumab in eosinophilic granulomatosis with polyangiitis: a meta-analysis of eight studies","volume":"55","author":"Spataro","year":"2025","journal-title":"Eur J Clin Invest"},{"key":"R24-20260401","doi-asserted-by":"crossref","first-page":"696.e1","DOI":"10.1016\/j.anai.2021.01.035","article-title":"Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"126","author":"Manka","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R25-20260401","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/all.15934","article-title":"Eosinophilic granulomatosis with polyangiitis onset in severe asthma patients on monoclonal antibodies targeting type 2 inflammation: report from the European EGPA study group","volume":"79","author":"Caminati","year":"2024","journal-title":"Allergy"},{"key":"R26-20260401","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"75","author":"Mohammad","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R27-20260401","doi-asserted-by":"crossref","first-page":"e000905","DOI":"10.1136\/rmdopen-2019-000905","article-title":"Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"5","author":"Teixeira","year":"2019","journal-title":"RMD Open"},{"key":"R28-20260401","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2017-211897","article-title":"Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis","volume":"77","author":"Emmi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R29-20260401","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/rheumatology\/keae554","article-title":"Dupilumab for refractory chronic rhinosinusitis in eosinophilic granulomatosis with polyangiitis","volume":"64","author":"Padoan","year":"2025","journal-title":"Rheumatology (Oxford)"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:01:20Z","timestamp":1775030480000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001148","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]}}}